Berner MJ, Wall SW, Baek ML, Lane A, Greer AS, Wang K, Dobrolecki LE, Strope IS, Zhu Q, Zhang B, Lei JT, Lewis MT, Echeverria GV. Mitochondrial protein translation is a metabolic dependency of chemotherapy refractory triple negative breast cancer. Biorxiv. 26 Mar 2026. Doi:10.64898/2026.03.23.712647.
Baek ML*, Arriojas A*, Berner MJ, Zhurkevich A, Hinton AO, Meyer MD, Dobrolecki LE. Lewis MT, Zarringhalam K#, Echeverria GV#. Artificial intelligence-enabled automated analysis of transmission electron micrographs to evaluate chemotherapy impact on mitochondrial morphology in triple negative breast cancer. Biorxiv. 23 Feb 2025. Doi: 10.1101/2025.02.19.635300.
Lei JT, Dobrolecki LE, Huang C, Srinivasan R, Vasaikar S, Lewis AN, Sallas C, Zhao N, Cao J, Landua JD, Moon CI, Liao Y, Hilsenbeck SH, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan V, Wen B, Li K, Saltzman AB, Jain A, Malovannaya A, Wulf GM, Marangoni E, Li S, Kraushaar DC, Wang T, Damodaran S, Zheng X, Meric-Bernstram F, Echeverria GV, Anurag M, Chen X, Welm BE, Welm AL, Zhang B, and Lewis MT. Patient derived xenografts of triple negative breast cancer enable deconvolution and prediction of chemotherapy responses. Biorxiv. 08 Jan 2025. Doi: 10.1101/2024.12.09.627518.
Caggiano EG, Elizondo, ME, Hernandez AL, Waldrop T, Liu K, Gatica-Gutierrez H, Vargas S, Mims N, Acevedo Diaz A, Velasquez B,Neil D, Aguilar E, Meyer MD, Echeverria GV, Koong AC, Spiotto MT, Gustavsson AK, Schuler E. Mitochondrial Responses to Conventional and Ultra-high Dose Rate (FLASH) Radiation. Red Journal: International Journal of Radiation Oncology, Biology, Physics. 14 July 2026. Doi:10.1016/j.ijrobp.2026.07.006.
Tran Huynh AM, Lei JT, Brough R, Sallas C, Xu J, Pilcher JB, Gou X, Wang J, Dobrolecki LE, Fandino D, Berner MJ, Greer A, Song F, Latka S, Villanueva H, Arimura S, Mao S, Guo Z, Aramburu S, Chen A, Nguyen T, Gutierrez C, Lopez Terrada D, Lim B, Hilsenbeck SG, Lewis MT, Miles G, Mills J, Echeverria GV, Pettitt S, Powell S, Rosenberg SM, Tutt AN, Lord CJ, Ellis MJ, Anurag M. LIG1 loss in TP53-mutant triple negative breast cancer rewires DNA repair and convers sensitivity to PARP-ATR inhibitor combinations. Molecular Cancer Therapeutics. 15 Jul 2026. Doi.org/10.1158/1535-7163.MCT-26-0182.
Berner MJ*, Beasely HK*, Vue Z, Lane A, Vang L, Baek ML, Marshall AG, Killon M, Zeleke F, Shao B, Parker D, Peterson A, Rhoades S, Scudese E, Dobrolecki LE, Lewis MT, Hinton AO#, Echeverria GV#. Three-dimensional structural analysis of mitochondrial networks in a chemo-refractory patient-derived xenograft model of triple negative breast cancer. iScience. 19 June 2026. Doi:10.1016/j.isci.2026.115865.
Jiang Y, Abdulkareem N, Qi Y, Rinkenbaugh A, Wall SW, Zhang X, Shao J, Jeter Jones S, Cai S, Hancock F, Echeverria GV, Chang JT, Piwnica-Worms H. Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Science Advances. 3 Apr 2026. Doi:10.1126/sciadv.aec8684.
Dai Y, Pan X, Guo S, Ji S, Cao S, Montierth M, Jiang Y, Chang JT, Shi L, Shalapour S, Echeverria GV, Yates L, Staaf J, Lim B, Yuan Y, Wang Wenyi. Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple negative breast cancer. Cell Reports Medicine. 17 Feb 2026. Doi. 10.1016/j.xcrm.2026.102610.
Rinkenbaugh AL, Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones S, Zhang X, Powell E, Huo L, Lau R, Fu C, Gould R, den Hollander P, Ravenberg E, White JB, Rauch GM, Arun B, Yam C, Thompson AM, Echeverria GV, Moulder SL, Symmans WF, Chang JT, Piwnica-Worms HM. An annotated biobank of triple negative breast cancer patient derived xenografts featuring treatment naïve and longitudinal samples throughout neoadjuvant chemotherapy. Cancer Research. 13 Aug 2025. Doi:10.1158/0008-5472.CAN-24-5023.
Andrews HS, Bado IL, Beumer A, Chan IS, Cowden J, Denardi D, Echeverria GV, Gates BL, Gilliam M, Hodgdon C, Lee AV, Manusco J, Maues J, Oesterreich S, Papanicolaou M, Pendleton KE, Riter B, Shanahan K, Tran-Huynh AM, Viswanath P, Walker S, Welm AL, Williams MM, Wyatt GL, Newby J. The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research. NPJ Breast Cancer. 21 June 2025. Doi: 10.1038/s41523-025-00771-6.
Berner MJ, Wall SW, Echeverria GV. Regulation of mitochondrial gene expression in cancer: Mechanisms and therapeutic opportunities. British Journal of Cancer. 14 Aug 2024. Doi: 10.1038/s41416-024-02817-1
Strope IS, Bowie WZ, Pendleton KE, Echeverria GV, Zhu Q. Xenomake: a pipeline for processing and sorting xenograft reads from spatial transcriptomic experiments. Bioinformatics. 1 Nov 2024. Doi: 10.1093/bioinformatics/btae608.
Wall SW and Echeverria GV. Commentary: Avoiding extinction: Cancer-associated fibroblasts help TNBC out-run chemotherapy. Cancer Research. 15 Nov 2023. Doi: 10.1158/0008-5472.CAN-23-2770.
Pendleton KE, Wang K, Echeverria GV. Rewiring of mitochondrial metabolism in therapy-resistant cancers: Permanent and plastic. Frontiers in Cell and Developmental Biology. 13 Sept 2023. Doi:10.3389/fcell.2023.1254313.
Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Myers J, Lai S, Lu W, Stephan C, Powell R, Johnson F, Skinner H, Kazi J, Kazi M, Hu L, Threet A, Meyer M, Bankson J, Wang T, Davis J, Parker K, Harris M, Baek ML, Echeverria GV, Qi X, Wang J, Walsh A, Frederick M, Sandulache V. Evolution of cisplatin resistance through coordinate metabolic reprogramming of the cellular reductive state. British Journal of Cancer. 03 April 2023. Doi: 10.1038/s41416-023-02253-7.
Baek M, Lee JG, Pendleton KE, Berner MJ, Goff EB, Tan L, Martinez SA, Wang T, Meyer M, Lim B, Barrish JP, Lorenzi P, Porter W, Echeverria GV. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy. Oncogene. 22 Feb 2023. Doi: 10.1038/s41388-023-02596-8.
*Selected as 2023 Oncogene paper of the year
Echeverria GV#*, Cai S, Tu Y, Shao J, Powell E, Redwood A, Jiang Y, McCoy A, Rinkenbaugh A, Lau R, Trevarton A, Fu X, Gould R, Ravenberg E, Huo L, Candelaria R, Santiago L, Adrada B, Lane D, Rauch G, ang Q, White J, Chang JT, Moulder S, Symmans WF, Hilsenbeck SG, Piwnica-Worms H*. *Denotes co-corresponding authorship. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer from fine needle tumor aspirates. NPJ Breast Cancer. 10 Jan 2023. Doi:10.1038/s41523-022-00502-1. # co-corresponding author
Anurag M, Jaehnig E, Krug K, Lei JT, Bergstrom E, Kim BJ, Vashist T, Huynh A, Dou YU, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs R, Munzy D, Doddapennio H, Dobrolecki L, Rodriguez H, Roble A, Hiltke T, Lewis MT, Nangia J, Shafee M, Hagemann IK, Hoog J, Lim B, Osborne CK, Mani DR, Gilette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, and Ellis MJ. Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer. Cancer Discovery. 18 Aug 2022. Doi: 10.1158/2159-8290.CD-22-0200.
Stires H, Bado I, Brown T, Carlson M, Chan I, Echeverria GV, Ewald A, Lim B, Maues J, Oesterreich S, Riter B, Shanahan K, Newby J, Welm A. Improving the odds together: A framework for research scientists to include patient advocates in cancer research. NPJ Breast Cancer. 30 Jun 2022. Doi 10/1038/s41523-022-00440-y.
Mavrommati I, Johnson F, Echeverria GV, Natrajan R. Modeling and targeting breast cancer heterogeneity- every cell counts. NPJ Breast Cancer. 2021 Dec 21. Doi: 10.1038/s41523-021-00363-0.
Roarty KP, Echeverria GV. Laboratory models for investigating breast cancer therapy resistance and metastasis. Frontiers in Oncology. 2021 March 10. Doi: 10.3389/fonc.2021.645698. PMC7988094.
Baek L, Chang JT, Echeverria GV. Methodological advancements for investigating intra-tumoral heterogeneity in breast cancer at the bench and bedside. Journal of Mammary Gland Biology and Neoplasia. 2020 Dec 9. Doi: 10.1007/s10911-020-09470-3. PMC7960623.
Powell RT, Redwood A, Liu X, Gui L, Cai S, Zhou X, Tu Y, Qi Y, Jiang Y, Echeverria GV, Feng N, Ma X, Giuliani V, Marzalek JR, Heffernan TP, Vellano CR, Stephan C, Davies P, Chang JT, Moulder SL, Symmans WF, Piwnica-Worms H. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. Scientific Reports. 2020 Oct 21. 10(1):17899. Doi: 101038/s41598-020-74882-4. PMC7578025.
Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, McCoy A, Cai S, Tu Y, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Qu Y, Alvarez M, Califano A, Moulder S, Symmans W, Marszalek J, Heffernan T, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 2019 Apr 17. 11:488. Doi: 10.1126/scitranslmed.aav0936.
Echeverria GV*, Powell E*, Seth S*, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Shao J, Zhang X, Cai S, Wu W, Draetta G, Symmans F, Moulder S, Chang JT, Heffernan T#, Piwnica-Worms H#. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nature Communications. 2018 Nov 29. 9:5079. Doi: 10.1038/s41467-018-07406-4.
Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Tabue JH, Hollier BG, Ramirez-Pena EQ, Soundarajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, Mani SA. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene. 2016 Jun 13; doi: 10.1038/onc.2016.203.
Powell E, Shao J, Yuan Y, Chen H, Cai S, Echeverria GV, Mistry N, Decker K, Schlosberg C, Do K, Edwards J, Liang H, Piwnica-Worms D, Piwnica-Worms H. p53 deficiency linked to BTG2 loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in PDX models of triple negative breast cancer. Breast Cancer Research. 2016Jan 27;18(1):13. Doi:10.1186/s13058-016-0673-9.
Hsu T, Simon L, Heill N, Marcotte R, Sayad A, Bland C, Echeverria GV, Sun T, Kurley S, Tyagi S, Karlin K, Dominguez-Vidana R, Hartman J, Renwick A, Scorsone K, Bernardi R, Skinner S, Jain A, Orellana M, Lagisetti C, Golding I, Jun S, Neilson J, Zhang X, Cooper TA, Webb T, Neel B, Shaw CA, Westbrook TF. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17;525(7569): 384-8. Doi: 10.1038/nature14985.